EUVIMEDEUVIMED entdecken
Crossref

Daridorexant (Quviviq)

CDA-AMC

Canadian Journal of Health Technologies · 02.03.2026 · 6 (3)

DOI: 10.51731/cjht.2026.1363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 02.03.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Daridorexant (Quviviq), 25 mg oral tablet, 50 mg oral tablet. Indication: Quviviq (daridorexant) is indicated for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Zitieren

APA

CDA-AMC (2026). Daridorexant (Quviviq). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1363

Vancouver

CDA-AMC. Daridorexant (Quviviq). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1363

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Daridorexant (Quviviq)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {3},
  doi = {10.51731/cjht.2026.1363}
}
Kostenlos starten →